Kintegral Advisory LLC Has $1.35 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Kintegral Advisory LLC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% during the 4th quarter, HoldingsChannel reports. The fund owned 4,128 shares of the medical instruments supplier’s stock after selling 192 shares during the quarter. Kintegral Advisory LLC’s holdings in West Pharmaceutical Services were worth $1,352,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of West Pharmaceutical Services by 0.3% in the third quarter. State Street Corp now owns 3,214,448 shares of the medical instruments supplier’s stock worth $964,850,000 after purchasing an additional 10,060 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of West Pharmaceutical Services by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,740,183 shares of the medical instruments supplier’s stock worth $520,569,000 after buying an additional 12,850 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of West Pharmaceutical Services by 5,074.0% in the 4th quarter. Van ECK Associates Corp now owns 689,493 shares of the medical instruments supplier’s stock valued at $225,851,000 after acquiring an additional 676,167 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of West Pharmaceutical Services by 21.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier’s stock valued at $205,114,000 after acquiring an additional 122,361 shares during the last quarter. Finally, FMR LLC raised its holdings in West Pharmaceutical Services by 199.4% during the third quarter. FMR LLC now owns 595,775 shares of the medical instruments supplier’s stock worth $178,828,000 after acquiring an additional 396,780 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $210.72 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $197.01 and a 52-week high of $400.88. The stock has a market cap of $15.24 billion, a PE ratio of 31.50, a P/E/G ratio of 6.74 and a beta of 1.01. The firm has a 50-day moving average of $316.29 and a 200-day moving average of $310.62. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. The firm had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio is 12.56%.

Analyst Ratings Changes

WST has been the subject of a number of analyst reports. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their price target for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. KeyCorp decreased their price objective on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Citigroup assumed coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus price target of $344.00.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.